Chinese Herbal Medicines最新文献

{"title":"Therapeutic potential of polysaccharides in type 2 diabetes mellitus via multi-target modulation of gut microbiota","authors":"Xiaolong Shang,&nbsp;Guangdong Hu,&nbsp;Mingrui Zhang,&nbsp;Jin Zuo,&nbsp;Mengyan Wang,&nbsp;Jiangping Wu,&nbsp;Qiuyue Lv,&nbsp;Yuyan Zhou,&nbsp;Taili Shao,&nbsp;Guodong Wang","doi":"10.1016/j.chmed.2025.09.003","DOIUrl":"10.1016/j.chmed.2025.09.003","url":null,"abstract":"<div><div>Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by chronic hyperglycemia, which has recently emerged as a major global public health challenge owing to its increasing prevalence. An imbalance in intestinal microbiota can induce inflammation and insulin resistance by altering the secretion of its metabolites, such as lipopolysaccharides, branched-chain amino acids, short-chain fatty acids, and bile acids, ultimately leading to the development of T2DM. Owing to their notable pharmacological activity, minimal side effects, and low toxicity, polysaccharides have attracted significant attention. In particular, they can improve T2DM by modulating gut microbiota structure, promoting beneficial bacteria proliferation, and enhancing the integrity of the intestinal barrier. These comprehensive effects endow polysaccharides with great potential for treating T2DM. This review outlines the relationship between intestinal microbiota dysbiosis and T2DM. Subsequently, it delves into the mechanisms through which polysaccharides alleviate T2DM by modulating the gut microbiota, elucidating how polysaccharides achieve multi-target intervention in T2DM by modulating the structure and metabolism of gut microbiota. Finally, this review explores the impact of the structural characteristics of polysaccharides on the composition and function of gut microbiota and summarizes the structural characteristics of polysaccharides that can improve T2DM, providing new ideas for the development of polysaccharide functional foods and drugs to improve T2DM.</div></div>","PeriodicalId":9916,"journal":{"name":"Chinese Herbal Medicines","volume":"18 4","pages":"Pages 983-992"},"PeriodicalIF":11.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Charting a course for TCM revitalization and development","authors":"Yingqiu Xie","doi":"10.1016/j.chmed.2026.08.010","DOIUrl":"10.1016/j.chmed.2026.08.010","url":null,"abstract":"","PeriodicalId":9916,"journal":{"name":"Chinese Herbal Medicines","volume":"18 4","pages":"Page 1082"},"PeriodicalIF":11.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence empowering innovation in traditional Chinese medicine","authors":"Wei Chen,&nbsp;Shilin Chen","doi":"10.1016/j.chmed.2026.08.003","DOIUrl":"10.1016/j.chmed.2026.08.003","url":null,"abstract":"","PeriodicalId":9916,"journal":{"name":"Chinese Herbal Medicines","volume":"18 4","pages":"Pages 773-774"},"PeriodicalIF":11.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tongfengning ameliorates hyperuricemia via inhibiting gut microbiota dysbiosis-mediated TLR4/MAPK/NF-κB hyperactivation in intestinal epithelium","authors":"Jiemei Guo,&nbsp;Meiling Wang,&nbsp;Ruifang Yang,&nbsp;Siyuan Lin,&nbsp;Zejun Chen,&nbsp;Ling Qiu,&nbsp;Mengting Qiu,&nbsp;Yingjie Zhang,&nbsp;Tatyana Aleksandrovna Khrustaleva,&nbsp;Bin Huang,&nbsp;Yan Xiao,&nbsp;Youxin Su","doi":"10.1016/j.chmed.2026.03.001","DOIUrl":"10.1016/j.chmed.2026.03.001","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To elucidate the phytochemical basis and therapeutic mechanisms of Tongfengning (TFN), a traditional herbal formula used to treat hyperuricemia (HUA), by integrating multi-omics strategies and functional validation.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS/MS) was employed to identify the compounds in TFN. A HUA mouse model was induced using hypoxanthine (300 mg/kg) and potassium oxonate (250 mg/kg), followed by oral treatment with TFN at doses of 9.56, 19.11, 38.22 g/kg. Therapeutic efficacy was assessed via serum uric acid (UA) levels, renal function, intestinal barrier markers, and inflammatory mediators. Concurrently, 16S rRNA sequencing was utilized to analyze gut microbiota dynamics, and &lt;em&gt;in vitro&lt;/em&gt; co-culture experiments demonstrated that TFN-modulated microbiota protect intestinal epithelial cells (IECs). Mechanistically, network pharmacology and RNA sequencing identified critical signaling pathways, which were subsequently validated by Western blotting. Multivariate statistical approaches were systematically applied to establish relationships between microbiota and HUA biomarkers.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;TFN significantly reduced serum UA, adenosine deaminase (ADA), xanthine oxidase (XOD) levels (&lt;em&gt;P&lt;/em&gt; &lt; 0.01, 0.001), mitigated renal injury, and inhibited pro-inflammatory cytokines (&lt;em&gt;P&lt;/em&gt; &lt; 0.05, 0.01, 0.001). TFN reduced serum levels of diamine oxidase (DAO) and &lt;em&gt;D&lt;/em&gt;-lactate (&lt;em&gt;D&lt;/em&gt;-LA) (&lt;em&gt;P&lt;/em&gt; &lt; 0.001), enhanced intestinal mucosal integrity, upregulated UA transporters, and enhanced intestinal UA excretion (&lt;em&gt;P&lt;/em&gt; &lt; 0.05, 0.01, 0.001). TFN also restored the &lt;em&gt;Firmicutes&lt;/em&gt;/&lt;em&gt;Bacteroidetes&lt;/em&gt; (&lt;em&gt;F&lt;/em&gt;/&lt;em&gt;B&lt;/em&gt;) and mitigated microbiota dysbiosis. &lt;em&gt;In vitro&lt;/em&gt;, co-culturing TFN-modulated gut microbiota with IECs directly protected against HUA-induced damage. Integrated network pharmacology with &lt;em&gt;in vivo&lt;/em&gt;/&lt;em&gt;in vitro&lt;/em&gt; transcriptomics identified the Toll-like receptor 4/mitogen-activated protein kinase/nuclear factor-κB (TLR4/MAPK/NF-&lt;em&gt;κ&lt;/em&gt;B) axis as the key mechanism through which TFN exerts its therapeutic effects on HUA. Additionally, TFN decreased the abundance of Rhodobacteraceae, Halieaceae, Desulfocapsaceae, Anaerolineae, &lt;em&gt;Akkermansia&lt;/em&gt;, &lt;em&gt;Ilumatobacter&lt;/em&gt;, and &lt;em&gt;Clostridium&lt;/em&gt;, while increasing that of &lt;em&gt;Ruminococcus&lt;/em&gt;, Rikenellaceae, Prevotellaceae, &lt;em&gt;Alistipes&lt;/em&gt;, &lt;em&gt;Odoribacter&lt;/em&gt;, Erysipelotrichaceae, &lt;em&gt;Eubacterium&lt;/em&gt;, Muribaculaceae, &lt;em&gt;Monoglobus&lt;/em&gt;, &lt;em&gt;Harryflintia&lt;/em&gt;, and &lt;em&gt;Muribaculum&lt;/em&gt;, which were highly correlated with HUA markers or TLR4/MAPK/NF-&lt;em&gt;κ&lt;/em&gt;B pathway.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;This study delineates a mechanistic network connecting the anti-HUA effects of TFN to intestinal barrier restoration, UA excretion, gut microbiota ","PeriodicalId":9916,"journal":{"name":"Chinese Herbal Medicines","volume":"18 4","pages":"Pages 1041-1055"},"PeriodicalIF":11.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing TCM-derived active natural product drug discovery for novel drug targets: Insights from AI powered tools","authors":"Shangtao Wang,&nbsp;Jinling Zhang,&nbsp;Wenshuang Wang,&nbsp;Sihan Xu,&nbsp;Man Zhang,&nbsp;Yuanyuan Hou,&nbsp;Gang Bai","doi":"10.1016/j.chmed.2026.07.007","DOIUrl":"10.1016/j.chmed.2026.07.007","url":null,"abstract":"<div><div>The discovery of natural products targeting novel and underexplored biological targets is deemed essential, as it underpins the advancement of innovative therapeutics across a broad spectrum of diseases. With the rapid advancement of artificial intelligence (AI) and the application of diverse drug discovery strategies, including multi-omics integration, network target prediction, virtual screening, and drug-target interaction prediction, these strategies are profoundly shaping the field, and active natural product-based drug discovery from traditional Chinese medicine has entered a new phase. In this era, multimodal and high-dimensional data can be integrated within the context of big data to enhance both its theoretical foundations and technical capabilities. Despite these advancements, AI-driven natural product drug discovery still confronts substantial challenges, particularly those associated with ensuring data and research quality, as well as achieving more profound scientific discoveries. To obtain more precise and biomedically meaningful results, further innovations in this field are therefore required. In essence, integrating high-dimensional data, network modeling, and intelligent screening within a closed-loop validation framework empowers AI and big data paradigms to catalyze the precise discovery of bioactive constituents, thereby unlocking new frontiers in target-directed therapeutics for complex diseases.</div></div>","PeriodicalId":9916,"journal":{"name":"Chinese Herbal Medicines","volume":"18 4","pages":"Pages 775-777"},"PeriodicalIF":11.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discovery of Q-Markers in traditional Chinese medicine based on machine learning: Application and verification in Xiaoyao Heji","authors":"Guotao Chen,&nbsp;Jing Hu,&nbsp;Aijing Li,&nbsp;Yu Zeng,&nbsp;Qingmei Mo,&nbsp;Kairui Tang,&nbsp;Jiaxu Chen,&nbsp;Xinsheng Yao,&nbsp;Yongxia Guan,&nbsp;Guimin Zhang,&nbsp;Liangliang He,&nbsp;Zhihong Yao","doi":"10.1016/j.chmed.2026.08.020","DOIUrl":"10.1016/j.chmed.2026.08.020","url":null,"abstract":"<div><h3>Objective</h3><div>Identification of quality marker (Q-Marker) is central to the modernization and quality control of traditional Chinese medicine (TCM). Existing methods, though diverse, lack a unified and scalable strategy to address the chemical and pharmacological complexity of TCM prescriptions. This study established a machine learning-driven framework to integrate multi-source data and systematically prioritize Q-Marker, using Xiaoyao Heji (XYHJ), a modern antidepressant formulation derived from Xiaoyao San, as a case study.</div></div><div><h3>Methods</h3><div>Firstly, a dataset of 302 compounds was constructed by summarizing 14 reported Q-Marker discovery strategies and annotated with five core dimensions-compatibility, specificity, measurability, traceability, and effectiveness. Subsequently, five ranking models (RankNet, Random Forest, XGBoost, Linear Regression and K-Nearest Neighbors) were trained with 8-fold GroupKFold cross-validation and evaluated by normalized discounted cumulative gain (NDCG), mean average precision (MAP), and Recall. Thirdly, the optimal model was applied to XYHJ, followed by systematic characterization of chemical profiles, quantitative analysis, drug metabolism and pharmacokinetics (DMPK), quality transitivity, and bioactivity. Finally, Q-Markers were further validated through radar chart modeling, Monte Carlo simulations, and chemometric analyses.</div></div><div><h3>Results</h3><div>Through a comparison of the machine learning models, XGBoost outperformed other models, exhibiting high and stable performance with NDCG, MAP, and Recall values ranging from 0.84 to 0.95. For the first time, the XYHJ prescription was comprehensively evaluated across its chemical profile, DMPK properties, quantitative content, manufacturing traceability, and biological efficacy. Using the optimal XGBoost ranking model, 15 components were screened and ranked, successfully identifying paeoniflorin, albiflorin, and glycyrrhizic acid as critical Q-Marker. The reliability of the ranking approach was further validated by integrating a previously published radar chart model with Monte Carlo simulations with over 10 000 sampling iterations. Furthermore, fingerprint similarity and chemometric analysis demonstrated the effectiveness of these Q-Markers in distinguishing XYHJ produced through different manufacturing processes.</div></div><div><h3>Conclusion</h3><div>This study developed a machine learning-driven ranking framework that unifies multiple Q-Marker discovery strategies. Using XYHJ as a case study, this approach not only enhances its quality control system but also provides a valuable reference for the standardization and modernization of other TCM prescriptions.</div></div>","PeriodicalId":9916,"journal":{"name":"Chinese Herbal Medicines","volume":"18 4","pages":"Pages 887-902"},"PeriodicalIF":11.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Compatibility mechanism of Chrysanthemi Indici Flos compound against hepatocellular carcinoma based on balance of DNMTs/TET2","authors":"Zehui He,&nbsp;Cancan Guo,&nbsp;Fangping Zhang,&nbsp;Feifan Li,&nbsp;Yu Zhou,&nbsp;Leyi Ma,&nbsp;Xiaohui Wang,&nbsp;Yuefeng Bi","doi":"10.1016/j.chmed.2026.03.003","DOIUrl":"10.1016/j.chmed.2026.03.003","url":null,"abstract":"<div><h3>Objective</h3><div>At present, traditional Chinese medicine (TCM) compounds is widely used in tumor therapy. However, due to the current single and simplistic efficacy evaluation indicators that are detached from the guidance of TCM theory, the elucidation of its mechanisms of efficacy is hindered. Therefore, the compatibility mechanism of <em>Chrysanthemi Indici Flos</em> compound (YJHFF) against hepatocellular carcinoma based on DNA methyltransferases/DNA demethylase ten-eleven translocation 2 (DNMTs/TET2) balanced relationship was explored according to the concept of the overall balance of TCM.</div></div><div><h3>Methods</h3><div>This study screened the best compound compatibility ratio in the <em>in vitro</em> experiments, cell viability and DNMTs/TET2 balance were used as evaluation indicators to investigate the effects of single herb and different compatibility of compound on HepG2 and H22 cells. <em>In vivo</em> experiments were conduct on H22 liver orthotopic transplantation model mice. After treatment, the tumor tissues were observed by hematoxylin-eosin (HE), TUNEL and Ki67 immunohistochemical staining, respectively. The oxidative stress and liver function indicators in serum were detected by enzyme-linked immunosorbent assay. In addition, the proportion of tumor-infiltrating lymphocytes was detected by immunofluorescence staining. The mRNA expression levels of <em>DNMTs</em> and <em>TET2</em> in tumor tissues were detected by RT-PCR.</div></div><div><h3>Results</h3><div>The results of <em>in vitro</em> experiments showed that the cell proliferation inhibition rate was highly consistent with the change trend of DNMTs/TET2 balance, accordingly, this study obtained the optimal formula YJHFF. In the <em>in vivo</em> experiments, the tumor growth inhibition rate of YJHFF in 5 g/kg was 62.97%. Extensive necrosis, increased apoptosis and inhibited proliferation activity were observed in tumor tissue. Furthermore, the serum SOD activity was significantly increased, MDA, ALT, AST and AFP levels were significantly decreased, suggesting YJHFF could systematically alleviated oxidative stress and improved liver function. Besides, the infiltration of CD3⁺, CD4⁺ and CD8⁺ T lymphocytes increased significantly, indicating that the body’s anti-tumor immune response was enhanced. Finally, RT-PCR analysis confirmed that antitumor effects were closely related to the core mechanism of DNMTs/TET2 expression regulation and reconstruction of epigenetic balance.</div></div><div><h3>Conclusion</h3><div>This work confirmed the rationality and feasibility of the DNMTs/TET2 balance relationship as an evaluation indicator for the study of the compatibility mechanism of TCM compounds. The YJHFF screened under the guidance of DNMTs/TET2 balance has liver protection and tumor immune function, showing good anti-hepatocellular carcinoma effect.</div></div>","PeriodicalId":9916,"journal":{"name":"Chinese Herbal Medicines","volume":"18 3","pages":"Pages 725-736"},"PeriodicalIF":11.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148564374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibacterial and antibiofilm activity of novel nanofibers bandage formulated with Juniperus communis essential oil targeting antibiotic resistant bacterial strains","authors":"Mohannad N. AbuHaweeleh,&nbsp;Ahmad Hamdan,&nbsp;Menatalla Metwally Said,&nbsp;Maryam Hassiba,&nbsp;Robin Augustine,&nbsp;Anwarul Hassan,&nbsp;Nahla O. Eltai,&nbsp;Susu M. Zughaier","doi":"10.1016/j.chmed.2026.05.005","DOIUrl":"10.1016/j.chmed.2026.05.005","url":null,"abstract":"<div><h3>Objective</h3><div>The alarming increase in antimicrobial resistance (AMR) threatens current armament of antibiotics. This global threat to public health revived the search for plant-derived antimicrobial therapeutics. <em>Juniperus communis</em> L. has been used in folk medicine for centuries. This study aims to examine the antibacterial and antibiofilm activity of polycaprolactone (PCL) nanofiber bandages formulate with essential oil extracted from <em>J. communis</em> against clinically relevant ESKAPE (<em>Escherichia coli</em>, <em>Enterococcus faecium</em>, <em>Staphylococcus aureus</em>, <em>Klebsiella pneumoniae</em>, <em>Acinetobacter baumanii</em>, <em>Pseudomonas aeruginosa</em>, and <em>Enterobacter cloacae</em>) bacterial pathogens commonly causing nosocomial infections.</div></div><div><h3>Methods</h3><div>Bacterial growth curves and bactericidal assays were performed on antibiotic sensitive and resistant clinical bacterial strains collectively known as ESKAPE pathogens. Antibiofilm activity of Juniper essential oil (JEO) was tested against methicillin resistant <em>S. aureus</em> (MRSA) and <em>E. coli</em> individually in a 96-well plate, and the 96 well plate which contains the bacteria was incubated over night to allow biofilm formation and stained using crystal violet. The antibacterial activity of PCL-based nanofiber membrane formulated with various doses (2%, 4%, 6%, and 8%) of JEO was tested using disc diffusion method.</div></div><div><h3>Results</h3><div>JEO dilutions (50, 25 and 12.5 µL) demonstrated a dose-dependent antibacterial activity against tested strains and significantly reduced growth after 24 h. JEO also exerted antibiofilm activity against MRSA and <em>E. coli</em> strains that are resistant to antibiotics. Additionally, PCL nanofiber membranes formulated with 8% JEO inhibited MRSA growth as demonstrated by large zone of inhibition on agar plate.</div></div><div><h3>Conclusion</h3><div>JEO has antibacterial activity against ESKAPE pathogens. The potential application of JEO formulated in PCL nanofiber bandages is for wound dressing to treat surgical site infections, burns or skin ulcers.</div></div>","PeriodicalId":9916,"journal":{"name":"Chinese Herbal Medicines","volume":"18 3","pages":"Pages 758-766"},"PeriodicalIF":11.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148563622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-pathway targeting by natural products in chronic respiratory diseases: Opportunities, challenges, and future perspectives","authors":"Siqi Lin,&nbsp;Lili Li,&nbsp;Shiqing Zhuo,&nbsp;Liang Yu,&nbsp;Yu Huang,&nbsp;Xiaofei Chen,&nbsp;Huihui Ti","doi":"10.1016/j.chmed.2026.05.003","DOIUrl":"10.1016/j.chmed.2026.05.003","url":null,"abstract":"<div><div>Chronic respiratory diseases (CRDs) are multifactorial disorders driven by dysregulated inflammation, oxidative stress, and tissue remodeling. Conventional single-target therapies are insufficient to halt disease progression, underscoring the demand for alternative therapeutic approaches. Natural products, including bioactive compounds, herbal extracts, and traditional Chinese medicine (TCM) formulas, are characterized by their inherent multi-target properties and represent a promising intervention strategy for CRDs. This perspective emphasizes natural products as network modulators that can simultaneously regulate multiple signaling pathways. The integration of systems biology, network pharmacology, and artificial intelligence (AI) is crucial for deciphering their polypharmacological mechanisms. The clinical translation of natural products is anticipated to benefit from the implementation of several key strategies, including multi-omics integration, AI, targeted delivery, and blockchain-based quality control. By shifting from a reductionist to a network-centric view, natural products can fulfill their potential as next-generation therapeutics for CRDs.</div></div>","PeriodicalId":9916,"journal":{"name":"Chinese Herbal Medicines","volume":"18 3","pages":"Pages 638-642"},"PeriodicalIF":11.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13389992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148564409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tanshinone IIA alleviates isoproterenol-induced myocardial injury via NR4A1/GATA4 pathway-mediated suppression of EndMT and oxidative stress","authors":"Guanfeng Xu,&nbsp;Hang Wu,&nbsp;Jie Zhang,&nbsp;Yaxuan Wang,&nbsp;Chongyu Shao,&nbsp;Jiehong Yang,&nbsp;Jin Han,&nbsp;Haitong Wan","doi":"10.1016/j.chmed.2026.05.006","DOIUrl":"10.1016/j.chmed.2026.05.006","url":null,"abstract":"","PeriodicalId":9916,"journal":{"name":"Chinese Herbal Medicines","volume":"18 3","pages":"Pages 635-637"},"PeriodicalIF":11.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390055/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148564498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}